Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Vascular Biogenics Ltd. (VBLT : NSDQ)
 
 • Company Description   
Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel.

Number of Employees: 41

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.55 Daily Weekly Monthly
20 Day Moving Average: 281,623 shares
Shares Outstanding: 69.33 (millions)
Market Capitalization: $107.46 (millions)
Beta: 1.09
52 Week High: $3.04
52 Week Low: $1.10
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 5.44% 18.76%
12 Week 14.81% 26.23%
Year To Date -21.32% -3.86%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
8 HASATAT STREET
-
MODI`IN ,L3 7178106
ISR
ph: 972-8993-5000
fax: 972-8993-5001
ir@vblrx.com http://www.vblrx.com
 
 • General Corporate Information   
Officers
Dror Harats - Chief Executive Officer
Marc Kozin - Chairman
Sam Backenroth - Chief Financial Officer
Matt Trudeau - Chief Commercial Officer
Ruth Alon - Director

Peer Information
Vascular Biogenics Ltd. (CORR.)
Vascular Biogenics Ltd. (RSPI)
Vascular Biogenics Ltd. (CGXP)
Vascular Biogenics Ltd. (BGEN)
Vascular Biogenics Ltd. (GTBP)
Vascular Biogenics Ltd. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: M96883109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 69.33
Most Recent Split Date: (:1)
Beta: 1.09
Market Capitalization: $107.46 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.49 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.51
Price/Cash Flow: -
Price / Sales: 154.39
EPS Growth
vs. Year Ago Period: -8.33%
vs. Previous Quarter: -8.33%
Sales Growth
vs. Year Ago Period: -38.92%
vs. Previous Quarter: -42.35%
ROE
03/31/22 - -69.21
12/31/21 - -63.08
09/30/21 - -66.02
ROA
03/31/22 - -54.63
12/31/21 - -49.82
09/30/21 - -51.68
Current Ratio
03/31/22 - 4.21
12/31/21 - 5.53
09/30/21 - 6.75
Quick Ratio
03/31/22 - -
12/31/21 - 5.53
09/30/21 - 6.75
Operating Margin
03/31/22 - -4,894.40
12/31/21 - -3,895.83
09/30/21 - -3,612.61
Net Margin
03/31/22 - -4,894.40
12/31/21 - -3,895.83
09/30/21 - -3,612.61
Pre-Tax Margin
03/31/22 - -3,703.30
12/31/21 - -3,895.83
09/30/21 - -3,613.39
Book Value
03/31/22 - 0.62
12/31/21 - 0.73
09/30/21 - 0.79
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©